iav
major
caus
respiratori
tract
infect
caus
excess
morbid
mortal
everi
year
addit
season
outbreak
influenza
epidem
winter
month
novel
influenza
virus
occasion
introduc
human
popul
caus
pandem
introduct
iav
subtyp
caus
pandem
respect
recent
virus
swine
origin
caus
first
pandem
centuri
start
mexico
march
viru
spread
rapidli
contin
caus
diseas
especi
children
young
adult
addit
avian
iav
occasion
transmit
infect
poultri
man
especi
highli
pathogen
avian
influenza
virus
subtyp
caus
infect
human
rel
frequent
case
fatal
outcom
protect
individu
season
iav
infect
vaccin
prevent
measur
choic
especi
individu
high
risk
develop
complic
iav
infect
benefit
vaccin
like
elderli
patient
chronic
diseas
immunocompromis
individu
addit
vaccin
could
help
mitig
impact
pandem
outbreak
howev
three
scenario
vaccin
use
effect
first
certain
high
risk
group
respond
vaccin
poorli
like
frail
elderli
certain
immunocompromis
subject
secondli
case
antigen
mismatch
vaccin
may
induc
antibodi
fail
neutral
epidem
strain
optim
therefor
afford
protect
these
drift
variant
final
case
pandem
vaccin
may
becom
avail
late
case
pandem
circumst
mention
antivir
drug
may
use
treat
patient
infect
iav
altern
drug
use
prophylact
outbreak
situat
present
two
class
licens
antivir
drug
influenza
exist
first
adamantan
amantadin
rimantadin
inhibit
protonchannel
function
protein
protein
function
ionchannel
play
role
uncoat
genet
materi
essenti
step
viru
replic
cycl
class
antivir
drug
compris
neuraminidas
na
inhibitor
zanamivir
oseltamivir
na
act
receptor
destroy
enzym
play
role
releas
viral
particl
bud
infect
cell
na
inhibitor
analog
sialic
acid
substrat
enzym
use
drug
reduc
viru
replic
may
reduc
durat
influenza
ill
unfortun
use
antivir
drug
also
drawback
especi
use
inhibitor
may
caus
side
effect
includ
neurolog
gastrointestin
symptom
main
drawback
use
na
inhibitor
emerg
resist
strain
posit
select
rapidli
exampl
season
iav
resist
amantadin
emerg
asia
predomin
strain
ever
sinc
furthermor
virus
resist
adamantan
worldwid
addit
season
virus
isol
influenza
season
resist
oseltamivir
also
treatment
especi
immunocompromis
patient
shed
viru
extens
period
emerg
resist
strain
complic
clearli
need
novel
drug
use
treat
iav
infect
suffer
disadvantag
therefor
wish
assess
antivir
properti
recombin
spd
human
rhspd
porcin
rpspd
origin
variou
iav
potenti
antivir
drug
hypothes
iav
less
like
develop
resist
class
antivir
molecul
sinc
target
glycan
present
iav
spd
belong
collectin
famili
import
class
innat
immun
protein
involv
earli
respons
pathogen
collagen
ctype
lectin
mainli
produc
clara
cell
type
ii
pneumocyt
neutral
varieti
respiratori
pathogen
includ
bacteria
virus
respiratori
syncyti
viru
parainfluenza
viru
adenovirus
sar
coronaviru
iav
review
see
collectin
bind
glycoconjug
express
surfac
pathogen
via
carbohydr
recognit
domain
crd
import
spd
demonstr
studi
spd
knockout
mice
suscept
infect
iav
spd
compet
mice
furthermor
shown
spd
concentr
increas
iav
infect
administr
spd
inhibitor
infect
mice
increas
lung
viru
titer
compar
normal
infect
favour
biolog
properti
spd
vivo
prompt
investig
molecul
antivir
drug
especi
porcin
spd
pspd
show
promis
result
vitro
exhibit
uniqu
structur
featur
compar
spd
anim
speci
unlik
human
counterpart
contain
extra
cystein
collagen
domain
nglycosyl
sialic
acidrich
oligosaccharid
crd
potenti
import
extra
loop
region
sga
present
crd
could
play
role
sugarbind
properti
pspd
shown
pspd
isol
porcin
bronchoalveolar
lavag
pspd
display
higher
affin
iav
human
rat
spd
sinc
limit
number
iav
test
previou
studi
still
remain
unknown
rang
iav
strain
neutral
pspd
hspd
present
studi
investig
potenti
rpspd
rhspd
neutral
iav
subtyp
find
indic
rpspd
broadli
neutral
activ
may
promis
candid
antivir
drug
treatment
iav
isol
nativ
spd
perform
use
lung
surplu
pig
euthan
purpos
porcin
lung
tissu
describ
manuscript
collect
anim
initi
use
instruct
surgeon
specif
surgic
techniqu
accord
dutch
experi
anim
act
ethic
assess
requir
primari
aim
experiment
procedur
conduct
anim
ethic
assess
mandatori
secondari
purpos
use
tissu
organ
collect
carcass
carcass
obtain
form
facil
utrecht
univers
netherland
medisch
ethisch
toets
commissi
metc
erasmu
medic
center
exempt
studi
review
accord
dutch
law
requir
sinc
studi
subject
experiment
treat
ask
chang
normal
routin
waiv
need
consent
due
fact
sampl
receiv
surplu
materi
surgic
specimen
patient
identifi
remov
followup
inform
obtain
materi
obtain
archiv
depart
patholog
eramu
medic
center
rotterdam
netherland
thirti
virus
select
base
subtyp
speci
origin
includ
avian
swine
human
iav
subtyp
characterist
strain
list
tabl
virus
propag
madindarbi
canin
kidney
mdck
atcc
cell
describ
previous
cultur
supernat
infect
mdck
clarifi
low
speed
centrifug
aliquot
store
use
infecti
viru
titer
determin
describ
previous
three
recombin
virus
prepar
reassort
strain
revers
genet
describ
previous
basic
cleavag
site
ha
protein
delet
sitedirect
mutagenesi
nativ
pspd
npspd
isol
pig
lung
describ
previous
purpos
six
month
old
surplu
pig
use
euthan
purpos
short
npspd
isol
lung
lavag
affin
purif
method
use
mannansepharos
bead
elut
bead
edtacontain
buffer
npspd
purifi
use
gel
filtrat
chromatographi
rpspd
express
purifi
character
describ
van
eijk
et
al
manuscript
prepar
rhspd
produc
base
upon
fulllength
hspd
clone
provid
dr
ec
crouch
washington
univers
st
loui
usa
briefli
spd
sequencecontain
pupe
express
plasmid
transfect
cell
atcc
use
protocol
previous
describ
kamen
et
al
express
media
harvest
day
solut
ad
mm
final
concentr
media
affin
purifi
mannanagaros
elut
edta
contain
buffer
mm
hepe
nacl
mm
edta
ph
elut
spd
separ
size
exclus
chromatographi
differ
assembl
form
trimer
dodecam
endotoxin
level
determin
toxinsensor
lal
assay
kit
rang
spd
bind
spd
viral
ha
interfer
bind
viru
receptor
assess
hi
twofold
dilut
spd
peanut
agglutinin
sigma
aldrich
schneeldorf
germani
includ
neg
control
made
use
dulbecco
phosphat
buffer
salin
contain
pb
contain
mm
mm
pbscm
gibco
grand
island
usa
dilut
spd
hemagglutin
unit
hau
respect
virus
dilut
pbscm
ad
h
turkey
erythrocyt
ad
hemagglutin
pattern
read
h
incub
room
temperatur
neg
control
experi
also
perform
pb
without
demonstr
spd
activ
transient
calcium
phosphatemedi
transfect
cell
perform
essenti
previous
describ
briefli
seed
well
well
plate
hour
transfect
plasmid
ha
np
gene
influenza
virus
brief
plasmid
dna
mix
calcium
phosphat
total
volum
water
hb
nacl
hepe
ph
ad
dropwis
mixtur
left
room
temperatur
minut
dna
mixtur
transfer
cell
incub
overnight
cell
wash
pbscm
incub
rpspd
one
hour
cell
incub
without
rpspd
includ
neg
control
wash
pbscm
cell
incub
monoclon
antibodi
direct
pspd
abd
serotec
oxford
uk
dilut
pbscm
minut
room
temperatur
cell
wash
pbscm
incub
fitclabel
goat
antimous
igg
antibodi
prepar
abd
sigmaaldricht
minut
room
temperatur
wash
cell
analyz
use
fluoresc
microscop
axiovert
zeiss
sliedrecht
netherland
determin
neutral
capac
rpspd
infect
reduct
assay
use
end
variou
concentr
rpspd
peanut
agglutinin
incub
respect
viru
prepar
contain
dilut
pbscm
h
room
temperatur
subsequ
mixtur
transfer
mdck
cell
wash
pbscm
incub
h
cell
wash
pbscm
twice
pb
contain
mm
edta
cell
incub
h
cultur
medium
without
trypsin
prevent
secondari
infect
cell
iav
wash
pb
contain
edta
subsequ
trypsin
cell
suspens
transfer
vbottom
plate
wash
twice
pb
contain
fetal
bovin
serum
stain
viabil
use
amcyanlabel
livedead
stain
invitrogen
oregon
usa
wash
cell
fix
cytofix
bd
bioscienc
san
diego
ca
accord
manufactur
recommend
subsequ
cell
wash
twice
cytoperm
bd
bioscienc
san
diego
ca
incub
monoclon
antibodi
specif
viral
nucleoprotein
label
fluorescein
isothiocyan
fitc
dakocytom
glostrup
denmark
wash
twice
cell
analyz
flowcytometri
use
diva
softwar
viru
histochemistri
season
iav
use
virus
propag
mdck
cell
purifi
sucros
gradient
densiti
centrifug
incub
formalin
one
week
label
fitc
sigmaaldrich
saint
loui
mo
describ
previous
archiv
paraffinembed
human
tracheal
tissu
section
obtain
depart
patholog
erasmu
mc
ethic
approv
requir
concern
surplu
materi
surgic
specimen
patient
identifi
remov
followup
inform
obtain
archiv
paraffinembed
ferret
tracheal
tissu
section
obtain
depart
virolog
erasmu
mc
assess
viru
bind
trachea
tissu
perform
essenti
describ
previous
brief
fitclabel
viru
incub
tissu
section
bind
viru
detect
use
peroxidas
label
rabbit
antifitc
antibodi
prepar
dakocytom
glostrup
denmark
signal
amplifi
tyramid
signal
amplif
system
perkin
elmer
boston
variou
concentr
rpspd
peanut
agglutinin
neg
control
pokewe
neg
control
concanavalin
cona
posit
control
incub
hau
viru
h
dilut
made
pbscm
tissu
section
first
deparaffin
xylen
hydrat
ethanol
incub
min
subsequ
incub
tri
hcl
ph
contain
block
reagent
buffer
perkin
elmer
boston
tissu
section
incub
fitclabel
viru
h
absenc
presenc
rpspd
one
lectin
h
wash
slide
pb
contain
mm
edta
tween
develop
tissu
counterstain
haematoxylin
embed
glycerolgelatin
merck
whitehous
station
nj
exclud
steric
hindranc
bind
ha
recombin
na
use
na
inhibit
assay
tetramer
stabil
solubl
recombin
na
deriv
acrest
cdna
kindli
provid
dr
thierri
van
den
berg
var
brussel
viru
express
purifi
recombin
baculoviru
express
system
cell
describ
brief
baculoviru
infect
cell
cultur
medium
harvest
pass
filter
extract
volum
nbutanol
aquou
phase
contain
na
adjust
mm
ph
load
hydroxyapatit
column
equilibr
mm
ph
butanol
column
elut
use
linear
gradient
mm
ph
butanol
mm
ph
butanol
nacontain
fraction
pool
subsequ
load
blue
sepharos
column
follow
wash
step
mm
me
ph
glycerol
mm
bleu
sepharos
column
elut
mm
me
ph
glycerol
mm
nacl
final
polish
step
na
fraction
pg
column
equilibr
mm
me
ph
glycerol
mm
mm
nacl
purifi
recombin
na
aliquot
store
use
neuraminidas
inhibit
assay
adapt
protocol
shortli
ng
incub
overnight
variou
concentr
rpspd
concanavalin
posit
control
peanut
agglutinin
neg
control
sigma
aldrich
chemi
bv
germani
steinheim
fetuin
micron
tube
volum
adjust
ul
pbscm
next
day
period
reagent
g
sodium
metaperiod
ml
merckschuchardt
germani
hohenbrunn
ad
mixtur
incub
min
room
temperatur
arsenit
reagent
g
sodium
arsenit
g
anhydr
sodium
sulfat
ml
e
merck
germani
darmstadt
ad
mix
rest
brown
color
disappear
mixtur
transfer
pcr
plate
thiobarbitur
acid
reagent
g
anhydr
sodium
sulfat
g
thiobarbitur
acid
ml
sigma
aldrich
chemi
bv
germani
steinheim
ad
incub
min
min
ice
mixtur
transfer
micron
tube
warrenhoff
reagent
ad
tube
vortex
final
tube
centrifug
min
rpm
upper
butanol
phase
transfer
elisa
plate
measur
optic
densiti
spectrophotomet
infinit
tecan
wavelength
nm
percentag
inhibit
calcul
accord
formula
absorb
sampl
absorb
without
inhibitor
first
investig
whether
rpspd
similar
biolog
activ
iav
compar
npspd
isol
pig
lung
end
two
prepar
test
iav
swine
human
avian
origin
hi
assay
perform
three
time
independ
result
shown
figur
rpspd
inhibit
hemagglutin
iav
similar
extent
npspd
statist
differ
observ
furthermor
activ
prepar
shown
depend
presenc
calcium
ion
sinc
inhibit
observ
pb
without
assay
peanut
agglutinin
includ
control
lectin
inhibit
iavmedi
hemagglutin
minim
concentr
rpspd
still
prevent
hemagglutin
virus
test
determin
assay
perform
duplic
repeat
three
six
time
averag
minim
inhibitori
concentr
rpspd
calcul
viru
plot
figur
averag
less
rpspd
requir
prevent
hemagglutin
iav
swine
human
avian
subtyp
subtyp
figur
within
subtyp
differ
sensit
inhibitori
activ
rpspd
exist
depend
speci
virus
origin
apart
human
iav
subtyp
suscept
inhibitori
activ
rpspd
averag
alreadi
suffici
fulli
inhibit
hemagglutin
human
iav
exclud
avian
avianlik
swine
classic
swine
virus
subtyp
concentr
higher
respect
figur
classic
swine
viru
suscept
inhibit
rpspd
maximum
concentr
test
also
pandem
strain
rel
suscept
averag
inhibitori
concentr
figur
also
within
subtyp
humanderiv
strain
suscept
avian
swine
virus
minim
inhibitori
concentr
respect
figur
virus
subtyp
test
particular
suscept
high
concentr
rpspd
requir
prevent
hemagglutin
virus
respect
figur
cellderiv
rpspd
rhspd
prepar
assembl
two
form
partli
assembl
trimer
subunit
fullyassembl
oligomer
form
trimer
refer
multim
separ
two
form
gel
filtrat
chromatographi
inhibitori
capac
form
compar
respect
virus
hi
assay
shown
figur
e
f
specif
biolog
activ
multim
greater
trimer
averag
rpspd
multim
requir
inhibit
hemagglutin
influenza
virus
test
significantli
lower
p
mannwhitney
test
minim
inhibitori
concentr
trimer
influenza
viru
inhibit
trimer
rpspd
minim
concentr
test
figur
also
inhibit
influenza
virus
test
minim
inhibitori
concentr
multim
significantli
lower
p
mannwhitney
test
trimer
respect
figur
minim
inhibitori
concentr
multim
requir
inhibit
virus
wherea
trimer
rpspd
fail
inhibit
virus
maximum
concentr
test
figur
although
rpspd
rhspd
similar
structur
also
strike
differ
therefor
compar
inhibitori
capac
spd
deriv
two
speci
hi
assay
use
panel
altogeth
iav
found
rpspd
inhibit
iav
subtyp
effici
rhspd
rhspd
fail
inhibit
hemagglutin
virus
maximum
concentr
test
figur
minim
inhibitori
concentr
rpspd
rang
similar
pattern
observ
inhibit
virus
test
inhibit
rhspd
albeit
rel
high
concentr
rang
figur
comparison
rpspd
inhibit
hemagglutin
effici
virus
differ
minim
inhibitori
concentr
rpspd
rhspd
statist
signific
p
case
inhibit
observ
rhspd
rpspd
action
spd
depend
presenc
calcium
ion
data
shown
test
whether
multim
rhspd
would
potent
trimer
rhspd
form
inhibitori
capac
rhspd
multim
compar
trimer
figur
use
select
iav
figur
apart
two
individu
strain
minim
inhibitori
concentr
multim
slightli
lower
trimer
indic
modest
inhibitori
capac
rhspd
caus
absenc
multim
rhspd
prepar
use
immunofluoresc
demonstr
rpspd
bind
ha
human
influenza
virus
cell
transfect
plasmid
ha
np
gene
influenza
viru
express
use
spd
specif
monoclon
antibodi
bind
rpspd
observ
cell
transfect
plasmid
express
ha
gene
cell
transfect
plasmid
encod
np
gene
figur
without
rpspd
fluoresc
observ
confirm
specif
stain
plasmid
encod
ha
np
gene
influenza
viru
similar
result
obtain
data
shown
use
infect
reduct
assay
capac
rpspd
protect
mdck
cell
infect
respect
virus
test
peanut
agglutinin
includ
neg
control
fail
reduc
number
cell
infect
iav
use
data
shown
contrast
rpspd
inhibit
infect
mdck
cell
wide
rang
virus
subtyp
figur
iav
strain
test
dosedepend
reduct
number
infect
cell
observ
cellular
infect
assay
none
virus
test
fulli
inhibit
spd
highest
concentr
test
averag
inhibit
observ
pandem
virus
classic
swine
virus
avianlik
swine
virus
human
season
virus
except
virus
subtyp
inhibit
effici
highest
dose
rpspd
test
inhibit
achiev
swine
virus
human
avian
virus
lowest
concentr
test
reduct
infect
observ
human
virus
human
virus
virus
subtyp
poorli
inhibit
even
high
concentr
rpspd
use
iav
strain
inhibit
inhibit
observ
respect
also
determin
whether
rpspd
interact
na
abl
inhibit
enzymat
activ
end
purifi
recombin
neuraminidas
subtyp
instead
virionexpos
na
use
exclud
possibl
steric
hindranc
bind
rpspd
ha
shown
figur
peanut
agglutinin
inhibit
enzymat
activ
neuraminidas
significantli
contrast
rpspd
cona
inhibit
enzymat
activ
subtyp
na
test
although
rel
high
dose
rpspd
requir
achiev
maxim
inhibit
concentr
inhibit
enzymat
activ
na
acrest
activ
expect
oseltamivir
inhibit
neuraminidas
activ
effici
figur
assay
use
oseltamivir
inhibit
enzymat
activ
molecul
molecul
concentr
nm
effect
antivir
drug
rpspd
must
abl
interfer
bind
viru
cell
respiratori
tract
therefor
test
capac
rpspd
inhibit
attach
human
season
human
season
viru
tracheal
epitheli
viru
cell
use
virushistochemistri
shown
figur
virus
bind
epitheli
cell
ferret
trachea
visibl
red
precipit
preincub
fitclabel
viru
rpspd
prevent
bind
minim
dose
viru
viru
dose
prevent
bind
viru
complet
number
posit
cell
reduc
compar
incub
label
viru
absenc
rpspd
inhibit
viru
attach
depend
presenc
sinc
absenc
dose
rpspd
fail
prevent
attach
virus
two
control
lectin
peanut
agglutinin
pokewe
mitogen
fail
prevent
viru
attach
contrast
cona
includ
posit
control
sinc
high
affin
viral
hemagglutinin
block
viru
attach
concentr
data
shown
also
test
effect
rpspd
viru
attach
use
human
trachea
tissu
figur
dose
rpspd
fulli
prevent
bind
human
season
iav
dose
bind
viru
epitheli
cell
reduc
consider
compar
viru
attach
absenc
rpspd
present
studi
antivir
activ
rpspd
assess
wide
rang
iav
strain
collectin
ctype
lectin
function
antimicrobi
defens
molecul
innat
immun
system
develop
collectinbas
antivir
drug
use
welldefin
recombin
product
accept
venu
howev
biolog
properti
recombin
protein
need
resembl
nativ
protein
first
biochem
properti
rpspd
character
detail
compar
npspd
shown
rpspd
structur
function
ident
npspd
van
eijk
et
al
manuscript
prepar
studi
focus
antivir
properti
rpspd
compar
iavneutr
activ
npspd
isol
pig
lung
hi
assay
broad
panel
iav
strain
inhibitori
activ
prepar
compar
depend
presenc
calcium
ion
indic
abl
produc
biolog
activ
properli
fold
recombin
protein
also
compar
antivir
activ
rpspd
rhspd
gener
rpspd
potent
antivir
activ
rhspd
measur
hi
assay
exampl
two
pandem
strain
suscept
inhibit
rhspd
agreement
previou
studi
contrast
rpspd
inhibit
hemagglutin
virus
although
rel
high
dose
requir
furthermor
rhspd
fail
inhibit
hemagglutin
swine
iav
subtyp
avian
human
virus
inhibit
ineffici
sinc
least
rhspd
rpspd
requir
thu
conclud
rpspd
inhibit
broader
rang
iav
effect
rhspd
therefor
studi
detail
rpspd
inhibit
hemagglutin
virus
also
reduc
infect
mdck
cell
virus
virus
subtyp
inhibit
ineffici
high
dose
requir
observ
inhibit
assay
rhspd
also
fail
neutral
virus
subtyp
demonstr
previous
interest
note
human
virus
suscept
action
rpspd
rhspd
origin
pig
bird
speci
differ
may
explain
differ
glycosyl
ha
human
iav
contain
put
nlink
glycosyl
site
avian
swine
virus
allow
spd
interact
ha
effici
crd
domain
shown
rhspd
potenc
rpspd
superior
rhspd
may
explain
structur
differ
compar
rhspd
rpspd
addit
loop
crd
addit
glycosyl
site
addit
cystein
collagen
domain
shown
sialic
acidrich
nlink
glycan
crd
provid
addit
mode
interact
like
sialic
acid
receptor
present
tip
viral
hemagglutinin
molecul
howev
contribut
featur
superior
antivir
activ
rpspd
need
elucid
observ
fulli
assembl
rpspd
neutral
iav
better
trimer
form
line
reason
mention
like
multimeris
increas
avid
spd
molecul
increas
number
crd
interact
iav
simultan
anoth
potenti
viral
target
could
bound
inhibit
rpspd
na
iav
shown
previous
inhibit
enzymat
activ
na
success
inhibit
viru
replic
viral
spread
class
exist
antivir
drug
base
principl
investig
whether
iav
na
also
glycosyl
inhibit
rpspd
use
contrast
studi
recombin
na
molecul
exclud
interfer
enzymat
activ
bind
rpspd
ha
although
enzymat
activ
inhibit
certain
extent
rel
high
rpspd
dose
requir
achiev
therefor
conclud
bind
rpspd
viral
ha
like
potent
mode
antivir
action
bind
na
note
reduct
infect
mdck
cell
observ
correl
inhibit
hemagglutin
activ
iav
provid
addit
evid
ha
primari
target
rpspd
interact
rpspd
viral
ha
prevent
attach
viru
target
cell
basi
neutral
effect
rpspd
inde
demonstr
rpspd
abl
bind
ha
influenza
virus
subtyp
figur
use
tissu
section
ferret
human
trachea
virushistochemistri
demonstr
rpspd
could
reduc
bind
human
iav
virus
epitheli
cell
human
ferret
upper
respiratori
tract
bind
viru
paraffinembed
tissu
may
reflect
virustissu
interact
vivo
exactli
howev
bind
pattern
variou
influenza
virus
respiratori
tract
tissu
obtain
variou
anim
speci
correl
pathogenesi
transmiss
virus
indic
pattern
virustissu
bind
assess
virushistochemistri
method
biolog
relev
conclus
result
obtain
present
studi
show
rpspd
potent
antivir
activ
wide
rang
iav
strain
vitro
rpspd
broad
neutral
activ
iav
neutral
differenti
depend
subtyp
anim
speci
origin
antivir
effect
mostli
mediat
bind
rpspd
viral
ha
therebi
prevent
bind
host
cell
receptor
demonstr
virushistochemistri
use
ferret
human
trachea
tissu
futur
studi
aim
deliveri
rpspd
assess
antivir
properti
vivo
